Last reviewed · How we verify
NCT07527715: MPS-CMR-DCM
Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy
trial testing left ventricular ejection fraction in Cardiomyopathy, Dilated in 2,000 participants. Currently enrolling.
1 December 2028
Quick facts
| Lead sponsor | Shandong Provincial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 December 2021 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2038 |
| Sites | 1 location across China |
Drugs / interventions tested
- left ventricular ejection fraction
Conditions studied
- Cardiomyopathy, Dilated — all drugs for Cardiomyopathy, Dilated →
- Prognosis — all drugs for Prognosis →
- Magnetic Resonance Imaging, Cardiac — all drugs for Magnetic Resonance Imaging, Cardiac →
- Death, Sudden, Cardiac — all drugs for Death, Sudden, Cardiac →
Sponsor
Shandong Provincial Hospital
Who can join
18 and older, any sex, with Cardiomyopathy, Dilated or Prognosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care. This observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results). The model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals. Beyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07527715
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiomyopathy, Dilated
Currently open trials in the same condition.
- NCT06546137 — National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Un · recruiting
- NCT06091475 — Therapy to Maintain Remission in Dilated Cardiomyopathy · NA · recruiting
- NCT05981092 — A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) · active not recruiting
- NCT05321875 — Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial) · Phase 3 · recruiting
- NCT04225520 — AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT · NA · active not recruiting
Other Shandong Provincial Hospital trials
Trials by the same sponsor.
- NCT07333287 — A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With A · Phase 2 · not yet recruiting
- NCT07180342 — An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorde · NA · recruiting
- NCT07284992 — SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC · Phase 2 · recruiting
- NCT06908382 — Neoadjuvant QL1706 Therapy for ESCC · Phase 2 · recruiting
- NCT06829797 — A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemothera · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07527715 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Provincial Hospital
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07527715.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing